| Could Prior Oral-bisphosphonate Administration Reduce the
Acute Phase Reaction of Zoledronate? |
| 경구용 비스포스포네이트의 사전 투여는 졸레드로네이트의
급성이상반응을 줄일 수 있는가? |
| 서성화1,조환성2,천상호2,정혜미3,박일형2* |
| 경북대학교 대학원 의과학과1, 경북대학교 의학전문대학원 정형외과학교실2, 경북대학교 대학원 통계학과3 |
|
|
| Abstract |
Objective
Bisphosphonates are the most commonly prescribed medications for the treatment of osteoporosis. This
study was designed to analyze the rate of acute phase reaction (APR) following Zoledronate 5 mg administration in
patients with osteoporosis who were treated with prior oral bisphosphonate for at least 2 weeks and to compare naïve
IV 5 mg Zoledronate.
Methods
Between July 2009 and October 2010, 27 patients with osteoporosis who were treated with prior oral
bisphosphonate for at least 2 weeks, and maximum 52 weeks (average 18.5 weeks) and were between 42-and
85-year-old at the time of study participation. We prospectively evaluated APR, including fever, flu-like symptoms,
headache, arthralgia, and myalgia, after 5 mg zoledronate by questionnaire. Additionally we assessed a visual
analogue scale (VAS) by 4-point categorical scale.
Results
In this study of 27 patients with osteoporosis, the frequency of APR, flu-like symptom and myalgia were
14.8% and 7.4% and fever, arthralgia, and headache were 3.7% respectively. In VAS, all reactions were mild. The
rate of APR rate in this study was statistically decreased compared to previous reports with zoledronate 5 mg IV in
bisphosphonate-naïve patients.
Conclusion
Prior oral bisphosphonate administration for at least 2 weeks could significantly reduce the APR of IV
zoledronate 5 mg. |
| Key Words:
Acute phase reaction, Oral bisphosphonate, Zoledronic acid |
|
PDF Links
Full text via DOI
Download Citation
